Cytk investor relations

WebApr 11, 2024 · SVP, Head of Investor Relations. 858.617.2361 . 201.847.5743 . [email protected] ... Cytokinetics (CYTK) Dips 20% so Far in 2024 on Setbacks. Cytokinetics (CYTK) declines 20% in the year so ... WebMar 15, 2024 · INVESTORS & MEDIA CALENDAR - UPCOMING EVENTS Webcast Barclays Global Healthcare Conference Mar 15, 2024 3:35 PM EDT Webcast Oppenheimer 33rd Annual Healthcare Conference Mar …

Billy Oglesby, PhD, Named Humana Dean at Thomas Jefferson …

WebMar 22, 2024 · Investors & Media. Cytokinetics, Inc. (NASDAQ: CYTK) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small … WebPipeline - Cytokinetics A pipeline powered by passion pipeline Research Pre-Clinical Phase 1 Phase 2 Phase 3 CARDIAC MUSCLE Omecamtiv Mecarbil (Heart Failure) … cy-con inc https://funnyfantasylda.com

Cytokinetics Incorporated (CYTK) Stock Price, News & Historical Data

WebMar 1, 2024 · Cytokinetics, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $1.96 million for the quarter ended December 2024, missing the Zacks Consensus Estimate by... WebMar 31, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in … Cytokinetics to Participate in Upcoming Investor Conferences. link: March 4, … ACC.23 Investor Event: REDWOOD-HCM Cohort 4 & FOREST-HCM 1.1 MB. Apr … Transfer Agent: Computershare 462 South 4th Street Louisville, KY 40202 Phone … Investor FAQ. IR/Media Contacts. Corporate Governance. Information … Investor FAQ. IR/Media Contacts. Corporate Governance. Information … Cytokinetics, Inc. is followed by the analysts listed above. Please note that any … WebJul 23, 2024 · SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the closing of its previously … cyc on stage

INVESTOR OVERVIEW Cytokinetics, Inc.

Category:Cytokinetics, Incorporated (CYTK) Q4 2024 Earnings Call …

Tags:Cytk investor relations

Cytk investor relations

CYTK - Cytokinetics Inc Stock Price Quote - NASDAQ

WebApr 10, 2024 · Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential... WebJan 7, 2024 · Cytokinetics Joanna Siegall Senior Manager, Corporate Communications, Investor Relations (425) 314-1721 Royalty Pharma Investor Relations and …

Cytk investor relations

Did you know?

WebDec 14, 2024 · CYTK Stock: Focus Back On Aficamten The FDA's experts took issue with the small impact omecamtiv mecarbil had on lowering the risk of death in patients at risk … WebCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) Yahoo. 04/03 16:00. UBS Adjusts Cytokinetics Price Target to $61 From $67, Maintains Buy Rating. MT Newswires. 04/03 10:50. Cantor Fitzgerald Adjusts Price Target on Cytokinetics to $59 From $61, Maintains Overweight Rating. MT Newswires.

WebSep 28, 2024 · Get the latest Cytokinetics Incorporated (CYTK) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals. WebApr 11, 2024 · A live audio webcast of the presentation will be available on the "News, Events, and Webcasts" tab via the Investor Relations section of the Company's website at https: ... Cytokinetics (CYTK ...

WebApr 10, 2024 · SOUTH SAN FRANCISCO, Apr 10, 2024 (GLOBE NEWSWIRE via COMTEX) -- SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that ... WebApr 6, 2024 · Cytokinetics started at overweight with $58 stock price target at J.P. Morgan. Dec. 10, 2024 at 6:59 a.m. ET by Tomi Kilgore. Biotech and Pharma Cytokinetics Stock …

WebJul 21, 2024 · M onday was a good day to be a Cytokinetics ( CYTK) investor. On what was a down day for the markets across the board, shares took off to the tune of 40% after the company announced positive... cy contingency\u0027sWebFeb 9, 2024 · The firm increased its portfolio allocation in CYTK by 43.66% over the last quarter. Polar Capital Holdings holds 2,672K shares representing 2.82% ownership of … cy contingent\u0027sWebApr 10, 2024 · CYTK. KK3A. SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated ( Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to participate in a fireside chat at the 22 nd Annual Needham Virtual Healthcare Conference on Monday, April 17, 2024 … cy continuation\u0027sWebFeb 22, 2024 · This biopharmaceutical company is expected to post quarterly loss of $1.22 per share in its upcoming report, which represents a year-over-year change of -238.9%. Revenues are expected to be $7.46... cy controversy\\u0027sWebApr 29, 2004 · Investor Relations Cytokinetics, Inc. 350 Oyster Point Blvd South San Francisco, CA 94080 Phone: 650-624-3060 Fax: 650-624-3070 Email: [email protected] Back to top Feb 14 2024 8:39 am EST Data Provided by Refinitiv. Minimum 15 minutes delayed. STOCK CHART SHAREHOLDER TOOLS Print … cyco nutrients feeding scheduleWebMar 16, 2024 · Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle … cy conveyancingWebJun 17, 2024 · SOUTH SAN FRANCISCO, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that, in response to a request from the U.S. Food and Drug Administration (FDA), the company recently provided additional pharmacokinetic analyses of omecamtiv mecarbil related to the company’s … cy controversy\u0027s